Thumzup Media to Integrate Dogecoin as Payment Option on App

TheCryptoTimesPublicado em 2025-10-16Última atualização em 2025-10-16

Thumzup Media Corporation, a US-based advertising technology firm and digital asset accumulator, has said that it is looking into adding Dogecoin (DOGE) as a payment option on its official application.

In an announcement in a post on X, the firm said that it is actively exploring Dogecoin as an alternative payment option for its users. “Dogecoin’s speed, low fees, and community appeal make it a natural fit for Thumzup’s reward ecosystem,” the firm said. 

The company emphasized in the official release that adding Dogecoin could make its reward system stronger, make payments easier, and speed up the global growth of its creator monetization model. 

Thumzup’s business model and DOGE’s potential inclusion

Thumzup lets people earn cash rewards right now for sharing real social media posts about products that advertisers are selling. The company wants to avoid traditional banking systems, lower the costs of middlemen, and make it possible to make micropayments almost instantly across borders by using DOGE. 

“Exploring Dogecoin integration is an important next step in our journey to create a scalable, low-friction rewards engine,” said Robert Steele, CEO of Thumzup, in the official statement. “If successful, this change could improve our unit economics and increase appeal to a broader, crypto-friendly creator base.”

Thumzup’s internal analysis says that using Dogecoin could help creators keep more of their money by lowering transaction fees, speeding up payouts, and bringing in new users from the global crypto community. Dogecoin’s design for frequent, low-value transactions aligns well with Thumzup’s pay-per-post model. 

Global partnerships of Thumzup 

The move is part of Thumzup’s larger digital asset strategy, which already includes holding Bitcoin and being able to invest in other major cryptocurrencies. Earlier this month, it said that it would spend $2.5 million on DogeHash Technologies to grow its Dogecoin mining business. 

The money will be used to buy and set up more than 500 ASIC miners, which could bring DogeHash’s total fleet to more than 4,000 rigs by the end of the year. Thumzup is about to buy DogeHash in an all-stock deal worth about $153.8 million. This investment comes before that. Upon completion, DogeHash Technologies Holdings, the new company, will trade on Nasdaq under the symbol XDOG.

The firm also clarified, though, that there is no set schedule for the rollout. Any use of DOGE payments will depend on successful technical validation, regulatory guidance, and phased pilot testing.

Also Read: Erebor Secures Conditional OCC Charter for Crypto Banking


Mobile Only Image

Leituras Relacionadas

Haiwei Huaxin's Official Seal Seized by Over a Hundred People, High-Stakes Corporate Battle's 'Nuclear Deterrence' in Action Again

On August 18th, Haowei Huaxin, a semiconductor firm specializing in gallium arsenide and gallium nitride wafers, reported that over a hundred individuals forcibly entered its offices and seized the company's official seals from a safe, including the corporate, contract, and party committee seals. The incident is the latest escalation in a protracted control dispute. Haowei Huaxin, established in 2010, was originally a joint venture. Control became contested after 2021 when Zhenwei Financial Holding injected capital, becoming the largest shareholder (34.01%), while former parent Haite High-Tech's stake was diluted to 33.79%. An agreed-upon governance structure collapsed, leading to mutual accusations. Haite claimed it was locked out of the subsidiary's premises, while also alleging improper management like livestock being kept on the chip fabrication site. After state-owned Qingdao Haiyue Holdings took over Zhenwei's stake in 2023, Haite accused it of illegally seizing control. Despite Haite winning several legal battles in 2024-2026, which affirmed its rights to nominate directors and the chairman, it failed to regain physical control or recover the seals. The stakes are high: market valuations for Haite's stake in Haowei Huaxin are estimated between 3.7 to 5 billion USD, yet it is only valued at about 83 million USD on Haite's books. Losing control effectively jeopardizes a significant portion of Haite's value. In response to the seal seizure, Haite framed it as a "shareholder rights protection" action agreed upon by five shareholders. This mirrors a pattern in Chinese corporate disputes where seizing physical seals becomes a tactic to paralyze the opponent's daily operations, seen in past conflicts at companies like Dangdang and Bitmain. However, such actions don't resolve underlying ownership issues; the opposing party can report the seals stolen, declare them void, and apply for new ones, albeit with significant delay. The incident underscores how fragile corporate governance can devolve into physical confrontations over symbols of authority, with control ultimately determined by law and shareholding, not possession of a seal.

marsbitHá 26m

Haiwei Huaxin's Official Seal Seized by Over a Hundred People, High-Stakes Corporate Battle's 'Nuclear Deterrence' in Action Again

marsbitHá 26m

Bernstein Interprets MRNA's 177% Surge: What's Fundamentals and What's Hype?

Bernstein's analysis of Moderna's 177% stock surge following positive Phase 3 results for its individualized neoantigen therapy (INT) in melanoma distinguishes fundamental drivers from market speculation. The clinical breakthrough is real: the INTerpath-001 trial met its primary and key secondary endpoints, providing crucial validation for mRNA technology in oncology beyond infectious diseases. However, Bernstein argues the magnitude of the stock move cannot be justified by this single trial's fundamentals alone. The surge was amplified by three key factors: 1) A re-rating of Moderna's mRNA platform potential for expansion into other cancers, 2) A massive short squeeze, given ~15% of shares were sold short pre-announcement, and 3) The compelling "cancer vaccine" narrative that fueled broader investor enthusiasm. While the melanoma success is significant, Bernstein cautions that replication in lung, kidney, and bladder cancers—which have different immunogenicity—is not guaranteed. Furthermore, INT's commercial model faces challenges: it's a personalized treatment, not a mass-market vaccine, implying higher production costs and potential margin pressures despite a projected multi-billion dollar peak sales opportunity. The report also notes sector rotation, with some funds moving from crowded AI/semiconductor trades into defensive healthcare stocks, adding further momentum. In conclusion, Bernstein maintains a "Market-Perform" rating and a $45 price target, far below the post-surge price. It views the current valuation as pricing in an optimistic multi-cancer platform success and efficient commercialization that are yet to be proven. The clinical inflection point is clear, but the earnings inflection point awaits validation across future trials and commercial execution.

marsbitHá 26m

Bernstein Interprets MRNA's 177% Surge: What's Fundamentals and What's Hype?

marsbitHá 26m

Trading

Spot
活动图片